University of Parma

Polyrizon's Intranasal Barrier Technology Shows Promise Against Respiratory Viruses and Allergens

- Polyrizon's PL-16 Viral Blocker demonstrated strong protection against H1N1 influenza through a reversible physical barrier mechanism that traps viral particles without cytotoxicity. - The company's PL-14 Allergy Blocker achieved over 60% targeted deposition in the nasal vestibule, the critical entry point for airborne allergens. - Both products utilize Polyrizon's proprietary Capture & Contain hydrogel platform, which forms a protective shield in the nasal cavity without pharmacological intervention. - The reversible mechanism of viral blocking confirms the formulations act as temporary physical barriers rather than viral inactivation agents, supporting their safety profile.